These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 28885675)
1. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675 [TBL] [Abstract][Full Text] [Related]
2. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681 [TBL] [Abstract][Full Text] [Related]
3. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related]
4. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Feng A; Tu Z; Yin B Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258 [TBL] [Abstract][Full Text] [Related]
5. Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer. Ma Y; Feng Q; Han B; Yu R; Jin Z Hereditas; 2023 Jul; 160(1):33. PubMed ID: 37518006 [TBL] [Abstract][Full Text] [Related]
6. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer. Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554 [TBL] [Abstract][Full Text] [Related]
7. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer. Jiao P; Hou J; Yao M; Wu J; Ren G Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267 [TBL] [Abstract][Full Text] [Related]
8. Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (NSCLC) patients by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS) assay. Chen J; Cheng GH; Chen LP; Pang TY; Wang XL Asian Pac J Cancer Prev; 2013; 14(5):3057-62. PubMed ID: 23803079 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer. Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746 [TBL] [Abstract][Full Text] [Related]
10. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471 [TBL] [Abstract][Full Text] [Related]
11. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768 [TBL] [Abstract][Full Text] [Related]
12. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094 [TBL] [Abstract][Full Text] [Related]
13. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC). Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555 [TBL] [Abstract][Full Text] [Related]
14. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453 [TBL] [Abstract][Full Text] [Related]
15. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin. Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715 [TBL] [Abstract][Full Text] [Related]
16. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808 [TBL] [Abstract][Full Text] [Related]
17. The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis. Yang CL; Liu SS; Ma YG; Liu YY; Xue YX; Huang B Med Oncol; 2012 Jun; 29(2):574-81. PubMed ID: 21312072 [TBL] [Abstract][Full Text] [Related]
18. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703 [TBL] [Abstract][Full Text] [Related]
19. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. Gao W; Liu Y; Qin R; Liu D; Feng Q Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836 [TBL] [Abstract][Full Text] [Related]
20. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]